Earnings Preview For Protalix BioTherapeutics
Protalix BioTherapeutics (AMEX:PLX) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here’s what investors…
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce U.S. FDA Acceptance Of A Resubmitted Biologics License Application For Pegunigalsidase Alfa For The Proposed Treatment Of Fabry Disease
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell
• AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Here is a look at the most-searched-for stocks on Benzinga Pro in the month of April.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial
Protalix BioTherapeutics Inc (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase…
Why Protalix BioTherapeutics Stock Is Soaring
Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint.
Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.